This invention relates to the field of
biomedical technology, and more particularly to a phosphatidyl
polymer, its preparation method, an mRNA phosphatidyl
polymer delivery system, and its applications. The phosphatidyl
polymer has the structure shown in Formula I. The phosphatidyl polymer can self-assemble with mRNA and modified amphiphilic molecules to form an mRNA
delivery system. This invention, by adjusting the
mass ratio of the phosphatidyl polymer to mRNA during complex preparation, can alter the organ-targeting characteristics of the complex
in vivo. With increasing proportion of phosphatidyl polymer in the
mass ratio formulation, the
target organ of the complex changes from the
spleen to the liver and then to the
lung. Compared to traditional mRNA delivery systems, this invention allows for control of the organ-targeting characteristics of the
delivery system simply by changing the
mass ratio formulation, achieves high
in vitro and
in vivo mRNA
delivery efficiency, reduces the difficulty and cost of large-scale
raw material production, and provides a new platform for efficient, precise, and universal mRNA delivery.